For most people, no: acute myeloid leukemia (AML) is not hereditary. The great majority of cases arise from genetic changes that are acquired during a person’s lifetime in the bone marrow, not passed down from a parent. However, a minority of patients do carry an inherited gene variant that raises their risk, and recognizing these families matters for treatment, donor selection, and relatives’ health.
In this article I explain the difference between acquired and inherited mutations, the syndromes linked to hereditary AML, the clues that should prompt genetic testing, and what a positive result means for a family.
What AML Is
AML is a fast-growing cancer of the myeloid cells, the immature marrow cells that normally develop into red blood cells, most white blood cells, and platelets. Leukemic blasts accumulate and crowd out healthy production, causing bone marrow failure. The result is anemia, infections, and bleeding.
AML is mostly a disease of older adults, although it can occur at any age. Symptoms include tiredness, breathlessness, fevers, frequent infections, easy bruising, nosebleeds, and bleeding gums. For the wider picture of leukemia types, see our leukemia guide.
Acquired Versus Inherited Mutations
Every AML is genetic in the sense that it is driven by DNA changes. The key question is where those changes come from.
- Somatic (acquired) mutations develop in a single marrow stem cell during life. They are found only in the leukemia and blood cells, not in eggs or sperm, so they cannot be passed to children. Examples include FLT3, NPM1, and IDH1/2 mutations.
- Germline (inherited) variants are present from conception in every cell of the body. They can be inherited from a parent and passed on to children. They do not cause AML on their own but make it more likely.
Known non-inherited risk factors include older age, previous chemotherapy or radiotherapy, high-dose radiation exposure, benzene exposure, smoking, and earlier marrow disorders such as myelodysplastic syndrome.
Inherited Syndromes Linked to AML
Modern classifications now recognize a category of myeloid neoplasms with germline predisposition. The main conditions are summarized below.
| Gene or syndrome | Usual inheritance | Typical clues |
|---|---|---|
| RUNX1 (familial platelet disorder with predisposition to myeloid malignancy) | Autosomal dominant | Lifelong mild low platelets or platelet dysfunction; relatives with leukemia or MDS |
| CEBPA (germline) | Autosomal dominant | AML in several relatives, sometimes at a young age |
| DDX41 | Autosomal dominant | AML or MDS often in later adulthood, which can make it look sporadic |
| GATA2 deficiency | Autosomal dominant | Recurrent unusual infections, warts, lymphedema, low monocytes |
| ANKRD26 and ETV6 | Autosomal dominant | Inherited low platelet counts |
| Fanconi anemia | Mostly autosomal recessive | Marrow failure in childhood, short stature, thumb or skin abnormalities |
| Telomere biology disorders | Variable | Nail changes, mouth patches, early grey hair, lung or liver fibrosis |
| Li-Fraumeni syndrome (TP53) | Autosomal dominant | Multiple cancers in the family at young ages |
Other inherited marrow failure syndromes, such as Shwachman-Diamond syndrome and severe congenital neutropenia, also carry an increased risk. Fanconi anemia is the best-known example and is covered in detail in our separate guide.
What About Down Syndrome?
Children with Down syndrome have a higher risk of leukemia, including a distinctive form of myeloid leukemia in early childhood. Down syndrome is a chromosomal condition that is usually not inherited from a parent, but it is a recognized constitutional risk factor.
When Should Hereditary AML Be Suspected?
Doctors consider germline testing when one or more of these clues are present:
- Two or more close relatives with AML, MDS, or unexplained low blood counts.
- A personal or family history of long-standing low platelets or a bleeding tendency.
- AML or MDS at an unusually young age.
- Physical features or infections suggesting one of the syndromes above.
- A mutation found in the leukemia at a level suggesting it may be present in every cell, such as certain CEBPA, RUNX1, DDX41, or TP53 findings.
A careful history of leukemia and other blood disorders in the family is one of the most useful tools we have.
How Genetic Testing Works
Testing for inherited variants is different from standard leukemia testing. Because the blood and marrow contain leukemic cells, germline testing usually uses a sample that reflects the body’s inherited DNA, most often cultured skin fibroblasts, and sometimes hair follicles. Cheek swabs can be contaminated by blood cells.
Results should be discussed with a genetic counselor. A positive result raises questions about insurance, family planning, and informing relatives, and some results are “variants of uncertain significance” that need careful interpretation.
Why It Matters for Treatment and Families
Identifying hereditary AML changes care in practical ways:
- Stem cell donor choice: a brother or sister who carries the same variant should generally not be the donor, so related donors are tested first.
- Treatment choices: some syndromes, such as Fanconi anemia and telomere disorders, make patients very sensitive to chemotherapy and radiation, so regimens are adjusted.
- Surveillance for relatives: carriers may be offered regular blood counts and specialist follow-up to detect changes early.
- Other cancer screening: syndromes like Li-Fraumeni need broader cancer surveillance.
Key Takeaways
- Most AML is caused by acquired mutations and is not passed down in families.
- A minority of cases involve inherited variants such as RUNX1, CEBPA, DDX41, or GATA2, or syndromes like Fanconi anemia.
- Family clusters, lifelong low platelets, and young age at diagnosis are key warning signs.
- Germline testing uses skin cells, not blood, and should include genetic counseling.
- A hereditary diagnosis affects donor selection, treatment, and relatives’ follow-up.
Frequently Asked Questions
If my parent had AML, will I get it?
Most likely not. In the usual case, a parent’s AML came from acquired mutations that cannot be inherited. Your risk is only substantially higher if the family carries a known predisposition gene, which a hematologist or genetic counselor can help assess.
Should my family be tested after my AML diagnosis?
Only if there are clues pointing to a hereditary cause. If a germline variant is confirmed in you, relatives can then be offered targeted testing for that specific variant.
Can inherited AML skip a generation?
It can appear to. Many predisposition genes do not always lead to leukemia, so a carrier parent may stay healthy while a child develops the disease. Recessive conditions such as Fanconi anemia also typically affect children of unaffected carrier parents.
Is hereditary AML treated differently?
The core treatment is similar, but details change. Donor selection, chemotherapy intensity, and long-term surveillance are all tailored to the specific syndrome.
